Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.
Ingmar Gorman, PhD
Advertisement
Dr Gorman is a study therapist in the phase 3 clinical trial for MDMA-assisted therapy and a co-founder of Fluence, a psychedelic education company that trains mental health providers in psychedelic treatments.
Articles by Ingmar Gorman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Precision Diagnosis: The New Paradigm for Neurocognitive Disorders
2
The Burning Out of Pharmacists
3
Can a Class Action Lawsuit Force Big AI to Make Chatbots Safer?
4
Insomnia in Older Adults: A Holistic Approach
5
